J Control Release. 2018 Dec 31. pii: S0168-3659(18)30753-3. doi: 10.1016/j.jconrel.2018.12.048. [Epub ahead of print]

Shapira-Furman T1, Serra R2, Gorelick N2, Doglioli M2, Tagliaferri V2, Cecia A2, Peters M2, Kumar A1, Rottenberg Y3, Langer R4, Brem H5, Tyler B6, Domb AJ7.

 

Author information:

1. Institute of Drug Research, School of Pharmacy-Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.

2. Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, United States.

3. Oncology Department, Hadassah Medical Center, Jerusalem, Israel.

4. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139-4307, United States.

5. Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, United States; Department of Oncology, Johns Hopkins University, Baltimore, MD, United States; Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, United States; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, United States.

6. Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, United States. Electronic address: btyler@jhmi.edu.

7. Institute of Drug Research, School of Pharmacy-Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel. Electronic address: avid@ekmd.huji.ac.il.

Abstract

 

Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel®) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel®. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel® the same size of wafers were formulated with TMZ. Wafers were loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4?weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9?L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11?days while the median survival for rats treated with systemic TMZ was 18?days. The group that received the BCNU alone wafer had a median survival of 15?days, the group that received the TMZ wafer alone had a median survival of 19?days, and the group treated with the BCNU-TMZ wafer had a median survival of 28?days with 25% of the animals living long term (p?<?.0038 vs. Control; p?<?.001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.

PMID: 30605703